Compare Cytokinetics Inc (CYTK) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Wheaton Precious Metals Corp — how do they compare? Cytokinetics Inc trades at $81.96 (market cap $11.12B), while Wheaton Precious Metals Corp trades at $108.48 (market cap $48.84B). The key difference: Wheaton Precious Metals Corp is far larger — about 4.4× Cytokinetics Inc's market cap, and Wheaton Precious Metals Corp pays a 0.72% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | WPM | |
|---|---|---|
Market Cap | $11.12B | $48.84B |
Sector | Technology | Basic Materials |
52-Week High | $87.26 | $165.72 |
52-Week Low | $33.23 | $88.32 |
Enterprise Value | $11.59B | $46.68B |
Dividend Yield | — | 0.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
Wheaton Precious Metals (WPM) trades at $107.83, down 2.02% today, showing bearish technical signals with strong resistance at $108-$110. Fundamentally, the company demonstrates robust performance with Q1 2026 EPS beating expectations at $1.28 versus $1.24, continuing a trend of earnings surprises. Revenue grew to $2.31 billion in 2025 with impressive 65.55% net income margin, though valuation ratios remain elevated with P/E at 27.25.
The stock presents a compelling opportunity with 80% analyst buy ratings and $161.75 consensus price target, representing 50% upside potential. Key risks include precious metal price volatility and the bearish technical outlook. Record cash flow generation and strong production growth support the positive fundamental story despite near-term price pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
